March 2, 2026 · Form 4 insider transaction
Robb Gary Charles bought 499 shares of Corcept Therapeutics Incorporated at $35.97 per share, a transaction worth $17.9K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.; In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.; Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 224 share underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.